The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?
Waldenström Macroglobulinemia (WM) is a rare, indolent B-cell lymphoma that primarily affects elderly individuals. Although frontline chemoimmunotherapy and Bruton’s tyrosine kinase inhibitors (BTKi) can provide durable responses, most patients eventually relapse, posing ongoing clinical challenges....
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Hematology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/frhem.2025.1624046/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|